Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | CAMK2D | Q13557 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511693 | 0.94 | PIM1 (0.49) | PIM1PIM3CNR2DRD2CAMK2D | |
| SCHEMBL6514615 | 0.87 | PIK3R1 (0.41) | PIM1PIM3CNR2CAMK2DALDH1A1 | |
| SCHEMBL6515094 | 0.86 | AKT1 (0.56) | — | |
| SCHEMBL6508656 | 0.84 | AURKA (0.53) | PIM1PIM3CNR2DRD2CAMK2D | |
| SCHEMBL6522395 | 0.82 | PLK1 (0.45) | PIM1PIM3CNR2CAMK2DALDH1A1 | |
| SCHEMBL6522415 | 0.82 | CHEK1 (0.46) | PIM1PIM3CNR2DRD2BRD4 | |
| SCHEMBL6506935 | 0.81 | PLK1 (0.44) | PIM1PIM3CNR2DRD2CAMK2D | |
| SCHEMBL6512484 | 0.79 | HTT (0.43) | BRD4 | |
| SCHEMBL6518602 | 0.79 | AURKA (0.41) | ALDH1A1 | |
| SCHEMBL6514357 | 0.77 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | PIM1 385/4885PIM3 609/4885CNR2 3139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.